` SWTX (SpringWorks Therapeutics Inc) vs S&P 500 Comparison - Alpha Spread

SWTX
vs
S&P 500

Over the past 12 months, SWTX has underperformed S&P 500, delivering a return of -1% compared to the S&P 500's 8% growth.

Stocks Performance
SWTX vs S&P 500

Loading
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
SWTX vs S&P 500

Loading
SWTX
S&P 500
Difference

Performance By Year
SWTX vs S&P 500

Loading
SWTX
S&P 500
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
SpringWorks Therapeutics Inc vs Peers

S&P 500
SWTX
ABBV
AMGN
GILD
VRTX
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

SpringWorks Therapeutics Inc
Glance View

Market Cap
3.7B USD
Industry
Biotechnology

SpringWorks Therapeutics Inc., a cutting-edge biopharmaceutical company, emerged from its inception as a strategic spin-out venture from the global pharmaceutical giant Pfizer. Born in 2017, the company cleverly positions itself at the forefront of the drug development process, with a keen focus on targeting rare diseases and cancer. SpringWorks leverages its robust pipeline of therapies, specifically designed to address significant unmet medical needs. Their approach revolves around the repurposing and reinvigoration of underappreciated and overlooked clinical molecules, which previously lacked the necessary backing to reach the market. This innovative approach allows SpringWorks to harness upstream R&D efforts while minimizing the typical time and resources required for de novo drug development. Earning its stripes in the field, SpringWorks generates revenue primarily through milestone and royalty agreements tied to its partnerships and co-development collaborations. Rather than relying solely on traditional sales of approved drugs, the company emphasizes strategic alliances with research institutions and pharmaceutical partners to advance its drug candidates. This co-development model extends its reach and augments the company's research capabilities, enabling SpringWorks to share risks and tap into broader resources. By nurturing innovations through collaboration, SpringWorks not only enriches its pipeline but also stands as a vanguard in transforming potential therapies into commercial realities, ultimately positioning itself as a linchpin in the orphan disease market.

SWTX Intrinsic Value
45 USD
Overvaluation 10%
Intrinsic Value
Price
Back to Top